

**Kentucky Department for Medicaid Services
Cabinet for Health and Family Services
High Cost Emerging Drugs - Drugs Estimated to be Over \$500,000 Annually
CY 2025 High Cost Emerging Drug Program As of 1/5/2026**

DRUG NAME	DATE APPROVED	CONDITION(S) TREATED	One-Time vs. Maintenance	ESTIMATED ANNUAL TREATMENT COST (WAC) IN (000s)
DUVYZAT	3/21/2024	DUCHENNE MUSCULAR DYSTROPHY (DMD)	MAINTENANCE	\$500 - \$1,219
OJEMDA	4/23/2024	PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA	MAINTENANCE	\$479 - \$958
PIASKY	6/20/2024	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	MAINTENANCE	\$460 - \$690
AUCATZYL	11/8/2024	RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	ONE-TIME	\$525
KEBILIDI	11/13/2024	AROMATIC L-AMINO ACID DECARBOXYLASE (AADC) DEFICIENCY	ONE-TIME	\$3,950
ZIIHERA	11/20/2024	UNRESECTABLE OR METASTATIC HER2-POSITIVE (IHC 3+) BILIARY TRACT CANCER	MAINTENANCE	\$369 - \$647
BIZENGRI	12/4/2024	ADVANCED, UNRESECTABLE, OR METASTATIC PANCREATIC ADENOCARCINOMA OR NON-SMALL CELL LUNG CANCER	MAINTENANCE	\$618
RYONCIL	12/19/2024	STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE	ONE-TIME	\$1,552
TRYNGOLZA	12/19/2024	FAMILIAL CHYLOMICRONEMIA SYNDROME	MAINTENANCE	\$595
VYKAT XR	3/26/2025	PRADER-WILLI SYNDROME	MAINTENANCE	\$480 - \$960
ZEVASKYN	4/29/2025	RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA	ONE-TIME	\$3,147
FORZINITY	9/19/2025	BARTH SYNDROME	MAINTENANCE	\$794
ITVISMA	11/25/2025	SPINAL MUSCULAR ATROPHY	ONE-TIME	\$2,590

Notes:

Drugs listed are those that are FDA approved and not included on the CY 2025 High Cost Drug Risk Pool drug list and meet qualifying parameters for inclusion.

Drugs listed are those with a Wholesale Acquisition Cost (WAC) or an estimated total annual treatment cost greater than \$500K.

Weight based dosing for therapies indicated for adults is calculated using patient weight of 50-100kg, or at the maximum dose published by the manufacturer.

**Kentucky Department for Medicaid Services
Cabinet for Health and Family Services
Potential High Cost Emerging Drugs - Drugs Estimated to be Over \$1,000,000 Annually
Drugs to be considered for the CY 2026 High Cost Emerging Drug Program**

GENERIC NAME	CONDITION(S) TREATED	ESTIMATED FDA APPROVAL DATE
KYGEVVI	THYMIDINE KINASE 2 DEFICIENCY	11/3/2025*
WASKYRA	WISKOTT-ALDRICH SYNDROME	12/9/2025*
TABELECLEUCEL	EPSTEIN-BARR VIRUS POSITIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD)	1/10/2026
CLEMIDSOGENE IANPARVOVEC (RGX-121)	HUNTER SYNDROME	2/8/2026
MARNETEGRAGENE AUTOTEMCEL (RP-L201)	LEUKOCYTE ADHESION DEFICIENCY	3/28/2026
TIVIDENOFUSP ALFA	HUNTER SYNDROME	4/5/2026
ORCA T	HEMATOLOGICAL MALIGNANCIES (AML, ALL, MDS)	4/6/2026
VUSOLIMOGENE ODERPAREPVEC (RP1)	MELANOMA	4/10/2026
DALNACOGENE PONPARVOVEC	HEMOPHILIA B	4/10/2026

Notes:

*Approved medications, but published WAC is not yet available

Drugs listed are those that are in the drug development pipeline and may be FDA approved in CY 2026.

Drugs listed are estimated to launch with a total annual treatment cost based on Wholesale Acquisition Cost (WAC) of greater than \$1M based on pricing of similar FDA approved therapies.

This list is not all inclusive as launch price is not known for all therapies ahead of launch. Other therapies may launch with an annual estimated cost of greater than \$1M.